Baird raises target for Cencora stock from USD 373 to USD 375

Published on 10/23/2026 at 11:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cencora signed a USD 2.4 billion oncology deal on October 21, 2026. Cencora stock costs EUR 301.30 on October 23, 2026 at Lang & Schwarz.

Acquisition and reporting dates

Baird raised its Cencora target to USD 375 from USD 373 on October 22, 2026.
Cencora agreed to a USD 2.4 billion oncology transaction on October 21, 2026.
Cencora stock trades at EUR 301.30 at 11:02 a.m. CEST at Lang & Schwarz on October 23, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Baird raised its price target for Cencora stock from USD 373 to USD 375 on October 22, 2026, keeping an Outperform rating, according to Markets Insider. The update followed Cencora's agreement to acquire American Oncology Network, making the oncology platform the central strategic issue for the stock.

Deal adds USD 2.4 billion scale

On October 21, 2026, Cencora announced a definitive agreement to acquire American Oncology Network, a physician-led network with more than 350 oncology providers across 21 states. The transaction values AON at an enterprise value of USD 2.4 billion, including USD 2.3 billion at closing and contingent value rights of up to USD 100 million, according to Cencora.

Cencora currently owns approximately 4 percent of AON and plans to acquire the remaining equity interests. The company expects the transaction to add to adjusted diluted earnings per share in the second year after closing, while regulatory clearances and AON shareholder approval remain closing conditions.

What does the deal mean for growth?

The immediate financial marker is Cencora's adjusted fiscal 2026 earnings outlook. The company now expects adjusted diluted earnings per share of at least USD 17.90, at the high end of its previous USD 17.75 to USD 17.95 range, reflecting strength in its U.S. Healthcare Solutions segment, according to Cencora. That guidance gives investors a measurable benchmark before the acquisition contributes to earnings.

Three dated steps for investors

On October 2, 2026, Cencora scheduled its fiscal fourth-quarter results for November 4, 2026, before the New York Stock Exchange opened, according to Cencora. On October 21, 2026, it announced the USD 2.4 billion AON transaction. On October 22, 2026, Baird lifted its target from USD 373 to USD 375.

The next substantiated date is November 4, 2026, when Cencora plans to release fiscal fourth-quarter results and discuss fiscal 2027 expectations. The earnings call is scheduled for 8:30 a.m. ET.

Stock price and valuation context

Cencora's primary listing is on the NYSE, where the stock closed at USD 338.48 on October 22, 2026. The finance data also shows a USD 244.82 to USD 377.54 52-week range and a market capitalization of USD 64.6 billion as of that date. The upcoming report will test whether the higher adjusted earnings floor and the oncology expansion can support the valuation.

Cencora stock was trading at EUR 301.30 at Lang & Schwarz on October 23, 2026, at 11:02 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Cencora stock.